CRL at a glance
Charles River Laboratories (CRL, SEC CIK 1100682) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 24, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Charles River Laboratories (CRL) shares worth $6.5 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Coleman Glenn on September 30, 2026 of 10 shares at $297.43 per share.
- In the last 90 days, CRL insiders reported 1 open-market purchase ($3K) and 17 open-market sales ($25.7M) on Form 4, a net sale of $25.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.0B
- −0.9% vs prior year
- Insiders · 90 days
- 1 buy · 17 sells
- Net −$25.7M
- 13F holders
- 34 funds
- $6.5B · −2 vs prior quarter
- Latest 8-K
- Sep 24, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 27, 2025
Management Discussion & Analysis
- Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
- Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
- Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
- Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
- Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk
Business Overview
- Core business model: Preclinical and clinical laboratory services for drug discovery and development
- No new products, services, or business segments introduced or emphasized in this fiscal year
- Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
- Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
- No errors or clawbacks of executive compensation reported during or after fiscal 2025
Risk Factors
- Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
- Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
- Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
- Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
- No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
AI summary of the CRL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 27, 2026
Management Discussion & Analysis
- DSA backlog $2.0B as of June 27, 2026, versus $1.9B as of December 27, 2025
- Annualized cost savings target approximately $300M by end of 2026
- Restructuring charges $23.1M for quarter and $54.6M for six months
- PathoQuest acquisition: additional 79% equity interest for $67.6M
Risk Factors
- No risk-factors section provided, preventing assessment of changes from the most recent 10-K
- Stock-repurchase authorization reduced to $700.0 million after $100.0 million spent during the quarter
- CEO 10b5-1 plan permits sales of up to 31,314 shares beginning September 1, 2026
AI summary of the CRL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor Day disclosure reiterates CRL’s business strategy and full-year 2026 guidance
- Long-term financial targets through 2030 provide updated benchmarks for valuation and execution
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results released August 5, 2026, covering the quarter ended June 27, 2026
- Financial performance details contained in the attached press-release exhibit
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved CRL’s 2026 Long-Term Incentive Plan at the May 5, 2026 annual meeting
- Plan enables future equity-based compensation for executives and other eligible employees
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 12 director nominees re-elected through 2027, with Abraham Ceesay receiving the weakest support: 35,798,426 votes for
- Executive compensation approved 41,356,139 to 2,716,251, supporting management’s pay framework
AI summaries of CRL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRL
Don't miss the next CRL filing
- Alerts as it files. A push when CRL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRL, by share count.
- Ask anything. An AI agent that reads every CRL filing and answers with sources.
CRL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Coleman Glenn | Buy | Sep 30, 2026 | 10 | $297.43 |
| FOSTER JAMES C | M | Aug 25, 2026 | 12,429 | - |
| FOSTER JAMES C | Sell | Aug 25, 2026 | 33,561 | $300.00 |
| FOSTER JAMES C | M | Aug 25, 2026 | 21,132 | - |
| FOSTER JAMES C | M | Aug 25, 2026 | 12,429 | $208.44 |
| FOSTER JAMES C | M | Aug 25, 2026 | 21,132 | $194.12 |
| Parisotto Shannon M | Sell | Aug 19, 2026 | 2,039 | $294.12 |
| Parisotto Shannon M | M | Aug 19, 2026 | 2,039 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $4.1B | $4.0B | $4.0B |
| Operating Income | $617.3M | $227.3M | $25.2M |
| Net Income | $474.6M | $22.2M | -$144.3M |
| Op. Margin | 14.9% | 5.6% | 0.6% |
| Net Margin | 11.5% | 0.5% | -3.6% |
| Balance Sheet | |||
| Total Assets | $8.2B | $7.5B | $7.1B |
| Equity | - | $3.5B | $3.2B |
| ROE | - | 0.6% | -4.6% |
| Per Share | |||
| EPS | $9.22 | $0.20 | $-2.91 |
| Cash Flow | |||
| Operating CF | $683.9M | $734.6M | $737.6M |
Source: XBRL data in Charles River Laboratories (CRL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CRL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $6.49B |
| Q1 2026 | 36 | $4.72B |
| Q4 2025 | 35 | $4.76B |
| Q3 2025 | 35 | $3.30B |
| Q2 2025 | 32 | $2.98B |
| Q1 2025 | 30 | $2.48B |
| Q4 2024 | 29 | $2.54B |
| Q3 2024 | 23 | $1.28B |
- FMR LLC (Fidelity)+783.5K (+23%)
- Invesco Ltd+587.5K (+25%)
- T. Rowe Price Group+380.2K (+34%)
- Citigroup+234.9K (+289%)
- Goldman Sachs Group+225.1K (+54%)
- Millennium Management−447.6K (-48%)
- Ameriprise Financial−228.2K (-21%)
- D.E. Shaw & Co−161.9K (-84%)
- Vanguard Portfolio Management LLC−83.7K (-4%)
- BlackRock−60.5K (-2%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 254 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 27, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - |
Related Health Care companies
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- INCY · IncyteServices-Commercial Physical & Biological Research
- IQV · IQVIAServices-Commercial Physical & Biological Research
- MXCT · MAXCYTE, INC.Services-Commercial Physical & Biological Research
- NRC · NATIONAL RESEARCH CORPServices-Commercial Physical & Biological Research
- OABI · OmniAb, Inc.Services-Commercial Physical & Biological Research
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CRL SEC filings: frequently asked questions
Are CRL insiders buying or selling?
In the last 90 days, Charles River Laboratories (CRL) officers, directors and 10% owners reported 1 open-market purchase worth $2,974 by 1 insider and 17 open-market sales worth $25.7 million by 6 insiders on Form 4, a net sale of $25.7 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRL stock?
As of June 30, 2026, the largest Charles River Laboratories (CRL) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($961.5 million), BlackRock ($861.5 million), Vanguard Capital Management LLC ($714.2 million), Invesco Ltd ($676.9 million), Vanguard Portfolio Management LLC ($501.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRL's revenue in fiscal year 2025?
For the fiscal year ended December 27, 2025 (FY2025), Charles River Laboratories (CRL) reported revenue of $4.0 billion (down 0.9% from FY2024) and a net loss of $144.3 million. Diluted EPS was -$2.91. The figures come from the XBRL data in the 10-K.
What are the main risks in CRL's latest 10-K?
In the 10-K filed February 18, 2026, Charles River Laboratories (CRL) flagged: Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair. Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution. (AI summary of the Risk Factors section.)
What did CRL report in its latest 8-K?
Charles River Laboratories (CRL) filed an 8-K on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor Day disclosure reiterates CRL’s business strategy and full-year 2026 guidance.
What are the latest CRL SEC filings?
Charles River Laboratories (CRL) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 24, 2026 and a Form 4 insider filing on October 2, 2026.
What is CRL's SEC CIK number?
Charles River Laboratories (CRL)'s SEC Central Index Key (CIK) is 1100682. EDGAR lists every CRL filing under that number.
Ask anything about CRL
The research agent reads CRL's filings, financials, insider trades and 13F holders, then answers with sources.